DORFSTRASSE 29, ZUG, V8
MoonLake Immunotherapeutics Enters Underwriting Agreement for 9M Shares
Investor Day June 22nd, 2026
MoonLake Immunotherapeutics Increases Equity Incentive Plan Shares by 5 Million
Master Commercial Supply Agreement with Vetter Pharma International
Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results
Annual Report to Security Holders
Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results
Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day
Q1
FY 2024
Q3
Q2
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Schedule 13D - Ownership Report
Submission Upload
Correspondence